Related Experiment Video

Updated: Jun 13, 2026

An Optimized Hemagglutination Inhibition (HI) Assay to Quantify Influenza-specific Antibody Titers
06:34

An Optimized Hemagglutination Inhibition (HI) Assay to Quantify Influenza-specific Antibody Titers

Published on: December 1, 2017

Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009-2010

O Wichmann1, P Stocker, G Poggensee

  • 1Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany. WichmannO@rki.de

Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin
|May 13, 2010
PubMed

Insights

The AS03-adjuvanted vaccine showed high effectiveness against the 2009 pandemic influenza A(H1N1) virus in Germany. One dose provided excellent vaccine effectiveness (VE) in adults aged 14-59 and moderately high VE in those 60 and older.

Area of Science:

  • Immunology
  • Epidemiology
  • Public Health

Background:

  • Germany exclusively used a monovalent AS03-adjuvanted vaccine during the 2009 influenza pandemic.
  • The vaccine was recommended as a single dose for all age groups to combat the pandemic influenza A(H1N1) virus.

Purpose of the Study:

  • To rapidly assess the vaccine effectiveness (VE) of the AS03-adjuvanted vaccine against the 2009 pandemic influenza A(H1N1) virus in Germany.
  • To evaluate VE across different age demographics.

Main Methods:

  • Utilized a screening method for rapid assessment of vaccine effectiveness.
  • Analyzed reported data from vaccinated and unvaccinated pandemic influenza cases.
  • Incorporated vaccination coverage estimates into the analysis.

Main Results:

  • Demonstrated excellent vaccine effectiveness (VE) of 96.8% in individuals aged 14-59 years.
  • Reported moderately high VE of 83.3% in individuals aged 60 years and older.
  • Confidence intervals indicated statistical significance for both age groups.

Conclusions:

  • The AS03-adjuvanted vaccine was highly effective in preventing pandemic influenza A(H1N1) infection in adults.
  • The single-dose vaccination strategy demonstrated significant public health benefits during the 2009 pandemic.

More Related Videos

A Luciferase-fluorescent Reporter Influenza Virus for Live Imaging and Quantification of Viral Infection05:21

A Luciferase-fluorescent Reporter Influenza Virus for Live Imaging and Quantification of Viral Infection

Published on: August 14, 2019

Measuring Influenza Neuraminidase Inhibition Antibody Titers by Enzyme-linked Lectin Assay08:11

Measuring Influenza Neuraminidase Inhibition Antibody Titers by Enzyme-linked Lectin Assay

Published on: September 6, 2016

Related Concept Videos

Vaccinations01:51

Vaccinations

Overview
Infectious Diseases and Their Occurrence01:28

Infectious Diseases and Their Occurrence

Infectious diseases appear in populations through various transmission patterns, influenced by pathogen characteristics, population immunity, environmental conditions, and social behavior. Understanding these patterns is essential for effective public health surveillance and intervention. These categories—sporadic, outbreak, epidemic, pandemic, and endemic—help frame the nature and scope of disease events.Sporadic diseases occur irregularly and infrequently, without a predictable temporal or...
Influenza01:27

Influenza

Influenza is an acute, highly communicable viral disease that affects the respiratory tract and is responsible for seasonal epidemics worldwide. Influenza A is the most prevalent type associated with widespread outbreaks and is subtyped based on two surface glycoproteins: hemagglutinin (H) and neuraminidase (N), as in H1N1. These glycoproteins are essential for viral infectivity, transmission, and immune recognition. Transmission occurs primarily through respiratory droplets and contaminated...